InteKrin Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.intekrin.com
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- InteKrin Therapeutics, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT02638038
A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Drug: PlaceboDrug: T0903131 Besylate
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- InteKrin Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT00952445
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Joslin Diabetes Center, Boston, Massachusetts, United States
🇺🇸St Louis Center for Clinical Research, Saint Louis, Missouri, United States
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- InteKrin Therapeutics, Inc.
- Target Recruit Count
- 367
- Registration Number
- NCT00631007
- Locations
- 🇲🇽
Comite Mexicano para la Prevencion de la Osteoporosis A.C., Mexico City, Mexico DF, Mexico
🇲🇽Centro Especializado en Diabetes y Obisidad (EDOPEC), Mexico City, Mexico DF, Mexico
🇲🇽Unidad Metabolica y Cardiovascular SC, Cuernavaca, Morelos, Mexico
© Copyright 2025. All Rights Reserved by MedPath